Assessment of Blood Viscosity in ARDS (Acute Respiratory Distress Syndrome)
ConditionARDS
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHospices Civils de Lyon
About this trial
Acute respiratory distress syndrome (ARDS) is characterized by damage to the alveolar-capillary membrane, resulting in hypoxemia, decreased pulmonary compliance, and hemodynamic changes.
Critical conditions (hypoxia; septic shock associated with ARDS) can alter blood viscosity. These changes in viscosity can affect blood flow and hemodynamics.
There is only one clinical study that has measured one of the determinants of blood viscosity in ARDS (deformability), even though other parameters are involved in viscosity (elongation, deformability, hematocrit, etc.), and it is possible to measure blood viscosity comprehensively. To date, therefore, no study has evaluated the various parameters of blood viscosity in ARDS.
The aim of this study is to investigate hyperviscosity in patients with ARDS and to assess whether this hyperviscosity correlates with respiratory or hemodynamic changes.
The investigators will therefore compare blood viscosity and its determinants in patients admitted to the intensive care unit for ARDS and in patients admitted for other reasons (excluding ARDS or sepsis/septic shock).
The investigators will also conduct a longitudinal assessment of changes in hemodynamic, respiratory, and viscosity parameters during ARDS
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥ 18 ans
with PaO₂/FiO₂ ≤ 200 mmHg (based on arterial blood gas analysis in patients receiving invasive or non-invasive mechanical ventilation or high-flow nasal oxygen therapy).
Participation agreement obtained (either from the patient themselves or from a relative)
Disqualifiers
ARDS that has been present for more than 72 hours
Terminally ill patient with death expected within 24 hours
Patient who has received a blood transfusion within the past month
Patient with a known hematologic malignancy (lymphoma; myeloma; acute or chronic leukemia)
Trial population
Intensive care patients treated at the Croix Rousse Hospital
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Blood draws (peripheral venous puncture)
Biological/VaccineProcedure performed by intensive care nurses. Case group : Daily blood draws (4 mL) for 7 days. Control group : blood draws (4 mL) on Day 1.
Blood draws (arterial catheter, central venous line, or Swan-Ganz catheter)
Other interventionCase group : For patients with an arterial catheter, central venous line, or Swan-Ganz catheter, an additional blood sample will be collected on Day 1.
Treatment groups
46 Participants
are divided into 2 treatment groupsGroup A: Case group2 interventions
Group B: Control group1 intervention
Trial outcomes
Primary outcomes
1
Comparison of Blood Viscosity in Patients with ARDS and Control Group on Day 1
Blood viscosity will be determined after complete oxygenation of the blood, at native hematocrit, at a temperature of 25 °C. Measurements will be performed at different shear rates (11.5, 22.5, 45, 90, and 225 s-¹) using a cone-plate viscometer (Brookfield DVII+ equipped with a CPE40 cone, Brookfield Engineering Labs, Natick, MA, USA). This technique is based on applying a well-defined shear rate gradient between a moving conical surface and a fixed flat surface, with the blood sample placed between them. The fluid subjected to this shear resists flow in proportion to its viscosity. The higher the viscosity, the greater the torque required to maintain motion. This approach allows for the precise measurement of the apparent viscosity of blood across a wide range of mechanical stresses, replicating the flow conditions encountered in the bloodstream. The value at 225 s-¹ will be used as the primary endpoint (with an accuracy of 5-10 centipoise at this shear rate).
Time frame
At day 1Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: